Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy

Research output: Contribution to journalReviewResearchpeer-review

Standard

Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. / Litvinov, Ivan V.; Shtreis, Anna; Kobayashi, Kenneth; Glassman, Steven; Tsang, Matthew; Woetmann, Anders; Sasseville, Denis; Ødum, Niels; Duvic, Madeleine.

In: OncoImmunology, Vol. 5, No. 7, e1175799, 02.07.2016.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Litvinov, IV, Shtreis, A, Kobayashi, K, Glassman, S, Tsang, M, Woetmann, A, Sasseville, D, Ødum, N & Duvic, M 2016, 'Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy', OncoImmunology, vol. 5, no. 7, e1175799. https://doi.org/10.1080/2162402X.2016.1175799

APA

Litvinov, I. V., Shtreis, A., Kobayashi, K., Glassman, S., Tsang, M., Woetmann, A., Sasseville, D., Ødum, N., & Duvic, M. (2016). Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. OncoImmunology, 5(7), [e1175799]. https://doi.org/10.1080/2162402X.2016.1175799

Vancouver

Litvinov IV, Shtreis A, Kobayashi K, Glassman S, Tsang M, Woetmann A et al. Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. OncoImmunology. 2016 Jul 2;5(7). e1175799. https://doi.org/10.1080/2162402X.2016.1175799

Author

Litvinov, Ivan V. ; Shtreis, Anna ; Kobayashi, Kenneth ; Glassman, Steven ; Tsang, Matthew ; Woetmann, Anders ; Sasseville, Denis ; Ødum, Niels ; Duvic, Madeleine. / Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. In: OncoImmunology. 2016 ; Vol. 5, No. 7.

Bibtex

@article{91c0a1c3f9174572ae41fdd1b68d8695,
title = "Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy",
abstract = "Most skin malignancies are caused by external and often preventable environmental agents. Multiple reports demonstrated that cutaneous T-cell lymphomas (CTCL) can occur in married couples and cluster in families. Furthermore, recent studies document geographic clustering of this malignancy in Texas as well as in other areas of the United States. Multiple infectious, occupational, and medication causes have been proposed as triggers or promoters of this malignancy including hydrochlorothiazide diuretics, Staphylococcus aureus, dermatophytes, Mycobacterium leprae, Chlamydia pneumoniae, human T-Cell lymphotropic virus type 1 (HTLV1), Epstein-Barr virus (EBV), and herpes simplex virus (HSV). In this report, we review recent evidence evaluating the involvement of these agents in cancer initiation/progression. Most importantly, recent molecular experimental evidence documented for the first time that S. aureus can activate oncogenic STAT3 signaling in malignant T cells. Specifically, S. aureus Enterotoxin type A (SEA) was recently shown to trigger non-malignant infiltrating T cells to release IL-2 and other cytokines. These signals upon binging to their cognate receptors on malignant T cells are then able to activate STAT3 and STAT5 oncogenic signaling and promote cancer progression and IL-17 secretion. In light of these findings, it might be important for patients with exacerbation of their CTCL symptoms to maintain high index of suspicion and treat these individuals for S. aureus colonization and/or sepsis with topical and systemic antibiotics.",
keywords = "Cutaneous T-cell lymphoma (CTCL), HTLV-1 and geographic clustering, IL-17, Mycosis fungoides (MF), S. aureus, STAT3, S{\'e}zary syndrome (SS), viruses",
author = "Litvinov, {Ivan V.} and Anna Shtreis and Kenneth Kobayashi and Steven Glassman and Matthew Tsang and Anders Woetmann and Denis Sasseville and Niels {\O}dum and Madeleine Duvic",
year = "2016",
month = jul,
day = "2",
doi = "10.1080/2162402X.2016.1175799",
language = "English",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor & Francis",
number = "7",

}

RIS

TY - JOUR

T1 - Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy

AU - Litvinov, Ivan V.

AU - Shtreis, Anna

AU - Kobayashi, Kenneth

AU - Glassman, Steven

AU - Tsang, Matthew

AU - Woetmann, Anders

AU - Sasseville, Denis

AU - Ødum, Niels

AU - Duvic, Madeleine

PY - 2016/7/2

Y1 - 2016/7/2

N2 - Most skin malignancies are caused by external and often preventable environmental agents. Multiple reports demonstrated that cutaneous T-cell lymphomas (CTCL) can occur in married couples and cluster in families. Furthermore, recent studies document geographic clustering of this malignancy in Texas as well as in other areas of the United States. Multiple infectious, occupational, and medication causes have been proposed as triggers or promoters of this malignancy including hydrochlorothiazide diuretics, Staphylococcus aureus, dermatophytes, Mycobacterium leprae, Chlamydia pneumoniae, human T-Cell lymphotropic virus type 1 (HTLV1), Epstein-Barr virus (EBV), and herpes simplex virus (HSV). In this report, we review recent evidence evaluating the involvement of these agents in cancer initiation/progression. Most importantly, recent molecular experimental evidence documented for the first time that S. aureus can activate oncogenic STAT3 signaling in malignant T cells. Specifically, S. aureus Enterotoxin type A (SEA) was recently shown to trigger non-malignant infiltrating T cells to release IL-2 and other cytokines. These signals upon binging to their cognate receptors on malignant T cells are then able to activate STAT3 and STAT5 oncogenic signaling and promote cancer progression and IL-17 secretion. In light of these findings, it might be important for patients with exacerbation of their CTCL symptoms to maintain high index of suspicion and treat these individuals for S. aureus colonization and/or sepsis with topical and systemic antibiotics.

AB - Most skin malignancies are caused by external and often preventable environmental agents. Multiple reports demonstrated that cutaneous T-cell lymphomas (CTCL) can occur in married couples and cluster in families. Furthermore, recent studies document geographic clustering of this malignancy in Texas as well as in other areas of the United States. Multiple infectious, occupational, and medication causes have been proposed as triggers or promoters of this malignancy including hydrochlorothiazide diuretics, Staphylococcus aureus, dermatophytes, Mycobacterium leprae, Chlamydia pneumoniae, human T-Cell lymphotropic virus type 1 (HTLV1), Epstein-Barr virus (EBV), and herpes simplex virus (HSV). In this report, we review recent evidence evaluating the involvement of these agents in cancer initiation/progression. Most importantly, recent molecular experimental evidence documented for the first time that S. aureus can activate oncogenic STAT3 signaling in malignant T cells. Specifically, S. aureus Enterotoxin type A (SEA) was recently shown to trigger non-malignant infiltrating T cells to release IL-2 and other cytokines. These signals upon binging to their cognate receptors on malignant T cells are then able to activate STAT3 and STAT5 oncogenic signaling and promote cancer progression and IL-17 secretion. In light of these findings, it might be important for patients with exacerbation of their CTCL symptoms to maintain high index of suspicion and treat these individuals for S. aureus colonization and/or sepsis with topical and systemic antibiotics.

KW - Cutaneous T-cell lymphoma (CTCL)

KW - HTLV-1 and geographic clustering

KW - IL-17

KW - Mycosis fungoides (MF)

KW - S. aureus

KW - STAT3

KW - Sézary syndrome (SS)

KW - viruses

U2 - 10.1080/2162402X.2016.1175799

DO - 10.1080/2162402X.2016.1175799

M3 - Review

C2 - 27622024

AN - SCOPUS:84976428040

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 7

M1 - e1175799

ER -

ID: 168928632